1.World Drug Report 2021. Austria: United Nations Publication; 2021.
2. Farooq SA, Rasooly MH, Abidi SH, Modjarrad K, Ali S. Opium trade and the spread of HIV in the Golden Crescent. Harm
Reduct J. 2017; 14(1): 47. doi: 10.1186/s12954-017-0170-1.
3. Shayan NA, Niazi AU, Moheb H, Mohammadi H, Ahmad Saddiqi KW, Dag O, et al. Epidemiology of drug use in
herat - Afghanistan. Addict Health. 2022;14(2):68-77. doi: 10.22122/ahj.2022.195606.1223.
4. Mansouri M, Naghshi S, Parsaeian M, Ghajarieh Sepanlou S, Poustchi H, Momayez Sanat Z, et al. Opium use and cancer
risk: a comprehensive systematic review and meta-analysis of observational studies. Int J Clin Pract. 2022;2022:5397449.
doi: 10.1155/2022/5397449.
5. Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: a systematic review and meta-analysis of
the odds ratios for opium use and the risk of bladder cancer. PLoS One. 2017;12(6):e0178527. doi: 10.1371/journal.pone.0178527.
6. Barlass U, Deshmukh A, Beck T, Bishehsari F. Opioid use as a potential risk factor for pancreatic cancer in the United States:
an analysis of state and national level databases. PLoS One. 2021;16(1):e0244285. doi: 10.1371/journal.pone.0244285.
7. Rashidian H, Zendehdel K, Kamangar F, Malekzadeh R, Haghdoost AA. An ecological study of the association between opiate use and incidence of cancers. Addict Health. 2016;8(4):252-60.
8. Rezaei S, Bakhshani NM, Fanaei H, Trofimova I. Opium effect in pregnancy on the dynamics of maternal behavior: testing a neurochemical model. Neuropsychobiology. 2021;80(2):147-57. doi: 10.1159/000512698.
9. Browne CJ, Godino A, Salery M, Nestler EJ. Epigenetic mechanisms of opioid addiction. Biol Psychiatry. 2020;87(1):22-33. doi: 10.1016/j.biopsych.2019.06.027.
10. Ghodsi M, Shahmohammadi M, Modarressi MH, Karami F. Investigation of promoter methylation of MCPH1 gene in
circulating cell-free DNA of brain tumor patients. Exp Brain Res. 2020;238(9):1903-9. doi: 10.1007/s00221-020-05848-1.
11. Quinonez SC, Innis JW. Human HOX gene disorders. Mol Genet Metab. 2014;111(1):4-15. doi: 10.1016/j.ymgme.2013.10.012.
12. Alvarado-Ruiz L, Martinez-Silva MG, Torres-Reyes LA, PinaSanchez P, Ortiz-Lazareno P, Bravo-Cuellar A, et al. HOXA9
is underexpressed in cervical cancer cells and its restoration decreases proliferation, migration and expression of epithelialto-mesenchymal transition genes. Asian Pac J Cancer Prev. 2016;17(3):1037-47. doi: 10.7314/apjcp.2016.17.3.1037.
13. Gurung PMS, Barnett AR, Wilson JS, Hudson J, Ward DG, Messing EM, et al. Prognostic DNA methylation biomarkers
in high-risk non-muscle-invasive bladder cancer: a systematic review to identify loci for prospective validation. Eur Urol
Focus. 2020;6(4):683-97. doi: 10.1016/j.euf.2019.02.012.
14. Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, et al. Detection of promoter DNA methylation
in urine and plasma aids the detection of non-small cell lung cancer. Clin Cancer Res. 2020;26(16):4339-48. doi:
10.1158/1078-0432.ccr-19-2896.
15. Shen N, Du J, Zhou H, Chen N, Pan Y, Hoheisel JD, et al. A diagnostic panel of DNA methylation biomarkers for lung
adenocarcinoma. Front Oncol. 2019;9:1281. doi: 10.3389/fonc.2019.01281.
16. Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular
carcinoma: a systematic review and meta-analysis. Cancer Med. 2020;9(4):1349-64. doi: 10.1002/cam4.2799.
17. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics. 2012;7(7):710-9. doi: 10.4161/epi.20524.
18. Krishnamurthy K, Mishra TK, Saxena A, Daga MK, Khurana N, Masroor M, et al. Evaluating NISCH and CDH1 promoter
hypermethylation in nonsmokers, cancer free smokers and lung cancer patients: a case control study. Indian J Clin
Biochem. 2019;34(4):458-64. doi: 10.1007/s12291-018-0767-5.
19. Maziveyi M, Alahari SK. Breast cancer tumor suppressors: a special emphasis on novel protein nischarin. Cancer Res.
2015;75(20):4252-9. doi: 10.1158/0008-5472.can-15-1395.
20. Li S, Wu N, Zhao TY, Lu GY, Wang ZY, Li F, et al. The role of IRAS/Nischarin involved in the development of morphine tolerance and physical dependence. Biochem Biophys Res Commun. 2019;512(3):460-6. doi: 10.1016/j.bbrc.2019.03.055.
21. Ostrow KL, Michailidi C, Guerrero-Preston R, Hoque MO, Greenberg A, Rom W, et al. Cigarette smoke induces methylation of the tumor suppressor gene NISCH. Epigenetics. 2013;8(4):383-8. doi: 10.4161/epi.24195.
22. Karami F, Noori-Daloii MR, Omidfar K, Tabrizi M, Hantooshzadeh S, Aleyasin A, et al. Modified methylated DNA immunoprecipitation protocol for noninvasive prenatal diagnosis of Down syndrome. J Obstet Gynaecol Res. 2018;44(4):608-13. doi: 10.1111/jog.13577.
23. Kozlenkov A, Jaffe AE, Timashpolsky A, Apontes P, Rudchenko S, Barbu M, et al. DNA methylation profiling of human prefrontal cortex neurons in heroin users shows significant difference between genomic contexts of hyperand hypomethylation and a younger epigenetic age. Genes (Basel). 2017;8(6):152. doi: 10.3390/genes8060152.
24. Ji H, Liu G, Xu X, Liu H, Xu L, Hu H, et al. Hypermethylation of the κ1 opioid receptor promoter in Chinese heroin and
methamphetamine addicts. Exp Ther Med. 2018;16(3):2392-8. doi: 10.3892/etm.2018.6514.
25. Sandoval-Sierra JV, Salgado García FI, Brooks JH, Derefinko KJ, Mozhui K. Effect of short-term prescription opioids on
DNA methylation of the OPRM1 promoter. Clin Epigenetics. 2020;12(1):76. doi: 10.1186/s13148-020-00868-8.
26. Muñoa-Hoyos I, Araolaza M, Urizar-Arenaza I, Gianzo M, Irazusta J, Subiran N. Sex dependent alteration of epigenetic
marks after chronic morphine treatment in mice organs. Food Chem Toxicol. 2021;152:112200. doi: 10.1016/j.fct.2021.112200.
27. Zhang J, Fan Y, Zhou J, Ma T, Gao K, Xu M, et al. Methylation quantitative trait locus rs5326 is associated with susceptibility
and effective dosage of methadone maintenance treatment for heroin use disorder. Psychopharmacology (Berl). 2021;238(12):3511-8. doi: 10.1007/s00213-021-05968-8.
28. Kosciuczuk U, Knapp P, Lotowska-Cwiklewska AM. Opioidinduced immunosuppression and carcinogenesis promotion theories create the newest trend in acute and chronic pain pharmacotherapy. Clinics (Sao Paulo). 2020;75:e1554. doi: 10.6061/clinics/2020/e1554.
29. Moossavi S, Mohamadnejad M, Pourshams A, Poustchi H, Islami F, Sharafkhah M, et al. Opium use and risk of pancreatic
cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2018;27(3):268-73. doi: 10.1158/1055-
9965.epi-17-0592.